All In Biotech

Drug Trial Radar · NCT04442022

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)

Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

501

Planned (sponsor's estimate)

Start

Sep 3, 2020

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Karyopharm Therapeutics IncIndustry
Sponsor type
Industry
First posted
Jun 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.

Conditions

  • Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventions

  • Selinexor (combination therapy)Drug

    Dose: 40 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • Selinexor (combination therapy)Drug

    Dose: 60 mg on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • Selinexor (combination therapy)Drug

    Dose: Selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • Placebo matching for Selinexor (combination therapy)Drug

    Dose: Placebo matching for selected dose of selinexor (from Phase 2) on Days 1 and 8 of each 21-day cycle for up to 6 cycles; Route of administration: oral

  • Rituximab (combination therapy)Drug

    Dose: 375 milligram per meter square (mg/m\^2) on Day 1; Route of administration: intravenous (IV)

  • Rituximab (combination therapy)Drug

    Dose: 375 mg/m\^2 on Day 1; Route of administration: IV

  • Gemcitabine (combination therapy)Drug

    Dose: 1000 mg/m\^2 on Days 1 and 8; Route of administration: IV

  • Dexamethasone (combination therapy)Drug

    Dose: 40 mg (20 mg if patient is more than 70 years old) on Days 1, 2, 3, and 4; Route of administration: oral or IV

  • Cisplatin (combination therapy)Drug

    Dose: 75 mg/m\^2 on Day 1; Route of administration: IV

  • Selinexor (continuous therapy)Drug

    Dose: 60 mg QW for each 28-day cycle until PD; Route of administration: oral

  • Placebo matching for Selinexor (continuous therapy)Drug

    Dose: Placebo matching for 60 mg selinexor QW for each 28-day cycle until PD; Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Overall Response Rate (ORR): Based on Lugano Criteria 2014Time frame: From date of initial randomization to the date of disease progression or initiating a new DLBCL treatment (maximum of 5 years from randomization)
  2. Phase 3: Progression-free Survival (PFS): Based on Lugano Criteria 2014Time frame: From date of initial randomization to the date of disease progression or death (maximum of 5 years from randomization)

Locations

38 sites in 6 countries. Site status is shown where the registry gives one.

  • Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Arizona Oncology Associates

    Tucson, Arizona

  • The Oncology Institute (TOI) Clinical Research

    Cerritos, California

  • Norton Cancer Institute, St. Matthews

    Louisville, Kentucky

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Stony Brook

    Stony Brook, New York

  • Texas Oncology - Tyler

    Tyler, Texas

  • The University of Texas Health Science Center at Tyler DBA UT Health East Texas HOPE Cancer Center

    Tyler, Texas

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School

    Huangpu, Shanghai Municipality, China

  • Zhongshan Hospital Fudan University

    Xuhui, Shanghai Municipality, China

  • Huaxi Hospital Sichuan University

    Chengdu, Sichuan, China

  • The first affiliated Hospital, Zhejiang University

    Hangzhou, Zhejiang, China

  • Assuta Ashdod Medical Center

    Ashdod, Israel

  • Soroka Medical Center

    Beersheba, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Assuta Medical Center - Ramat Hachayal

    Tel Aviv, Israel

  • AOU Ospedali Riuniti-Università Politecnica delle Marche Clinica di Ematologia

    Ancona, Ancona, Italy

  • UOC Ematologia ad Indirizzo Oncologico, AORN "Sant'Anna e San Sebastiano"

    Caserta, Caserta, Italy

  • National Cancer Institute

    Naples, Napoli, Italy

  • AOU Maggiore della Carità SCDU Ematologia

    Novara, Novara, Italy

  • DIP. Oncologia- Ematologia, UOSD Centro Diagnosie TerapiaDei Linfomi

    Pescara, Pescara, Italy

  • Fondatione Policlinico Universitario A. Gemelli

    Rome, Rome, Italy

  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello

    Palermo, Sicily, Italy

  • AOU City of Health and Science of Turin

    Turin, Torino, Italy

  • Institute of Hematology and Transfusion Medicine

    Warsaw, Poland

  • Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

  • Pratia MCM Krakow

    Krakow, Lesser, Poland

  • Szpitale pomorskie gdynia dept of haematology

    Gdynia, Pomeranian Voivodeship, Poland

  • Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytecki Szpital Kliniczny im. Jana Mikulicza - Radeckiego we Wrocławiu

    Wroclaw, Radeckiego, Poland

  • Pratia Onkologia Katowice

    Katowice, Silesian Voivodeship, Poland

  • CM Pratia Poznań

    Skorzewo, Wielkopolska, Poland

  • Institut català d'oncologia-hospital germans trias i pujol

    Badalona, Barcelona, Spain

  • Hospital Vall Hebron

    Barcelona, Barcelona, Spain

  • Institut Catala D'oncolocia

    Barcelona, Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Madrid, Spain

  • Hospital Virgen del Rocío

    Seville, Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.